BEVERLY HILLS, Calif.
, Sept. 21, 2012
/PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that Company advisor and advocate Dr. Jennifer R. Berman
, MD will appear on the internationally syndicated health focused TV talk show "The Doctors" this Monday, September 24
"Dr. Berman is one of the most in demand medical experts on the television talk show circuit today. Her recent taping of the Ricki Lake Show should only add to her reputation and celebrity status," stated Michael Borkowski, CEO of Eaton Scientific. "The Company" is thrilled with Dr. Berman's ongoing commitment as an active scientific advisor and advocate, as we move forward."
The Doctors is a syndicated health focused talk show airing daily in the U.S., Canada, Mexico, Australia, Ireland, Sweden and Finland. The hour-long daytime program was created by and is produced by the well-known Dr. Phil McGraw aka "Dr. Phil." The series is considered a spin-off of Dr. Phil and is the first talk show to be spun off from another talk show spin-off, as Dr. Phil itself is a spin-off of The Oprah Winfrey Show.
The Doctors show concept, which originated on Dr. Phil, mostly focuses on health and medical issues, as a team of medical professionals and celebrity guests/speakers discuss a range of various health-related topics and answer questions from viewers. The series is hosted by emergency room physician and former The Bachelor participant Dr. Travis Stork with pediatrician Dr. Jim Sears, obstetrician/gynecologist Dr. Lisa Masterson, and plastic surgeon Dr. Andrew Ordon. The series is distributed domestically and globally by CBS Television Distribution. The Doctors first aired September 8, 2008. In late August 2012, The Doctors was renewed through the 2015-2016 season. The show's fifth season started airing on September 10, 2012.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.